-
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 80 locations
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 74 locations
-
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
NCT06745583 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 2 locations
-
A Study of AMDX-2011P in Participants With Alzheimer's Disease
NCT06514001 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595 ·
Phase: Phase 2 ·
Ages: 55 Years to 85 Years ·
Sex: All (male and female) · 72 locations
-
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
NCT06996730 ·
Phase: Phase 2, Phase 3 ·
Ages: 25 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Study of NTRX-07 in Participants With Alzheimer's Disease
NCT07058688 ·
Phase: Phase 2 ·
Ages: 65 Years to 80 Years ·
Sex: All (male and female) · 6 locations
-
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
NCT06803823 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 38 locations
-
A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
NCT05413655 ·
Phase: Phase 2 ·
Ages: 50 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 37 locations
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 37 locations
-
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
NCT06995573 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 10 locations
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106 ·
Phase: Phase 1, Phase 2 ·
Ages: 35 Years to 85 Years ·
Sex: All (male and female) · 26 locations
-
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female) · 70 locations
-
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female) · 67 locations
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 110 locations
-
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT07599670 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female) · 12 locations
-
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
NCT07636811 ·
Phase: Phase 2 ·
Ages: 40 Years to 55 Years ·
Sex: All (male and female) · 3 locations
-
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
NCT07252440 ·
Phase: Phase 2 ·
Ages: 55 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213 ·
Phase: Phase 2 ·
Ages: 55 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673 ·
Phase: Phase 2, Phase 3 ·
Ages: 55 Years to 95 Years ·
Sex: All (male and female) · 149 locations
-
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
NCT07392723 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 1 location
-
Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
NCT07367815 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Alzheimer's Tau Platform: Master Protocol
NCT06957418 ·
Phase: Phase 2 ·
Ages: 50 Years to 80 Years ·
Sex: All (male and female) · 3 locations
-
Assess Fibrin in Brains With AD/ADRD
NCT05336695 ·
Phase: Phase 1, Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
NCT06489548 ·
Phase: Phase 2 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
NCT07236190 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female) · 1 location
-
Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk
NCT07007208 ·
Phase: Phase 2 ·
Ages: 60 Years to 100 Years ·
Sex: All (male and female) · 1 location
-
Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)
NCT07496918 ·
Phase: Phase 2 ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female) · 1 location
-
Bumetanide in Patients With Alzheimer's Disease
NCT06052163 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
CBD for Individuals at Risk for Alzheimer's Disease
NCT05822362 ·
Phase: Phase 2 ·
Ages: 55 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
COMMETS- Combination MCI Metabolic Syndrome
NCT06072963 ·
Phase: Phase 2 ·
Ages: 60 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Cannabidiol Medication Intervention Trial
NCT06014424 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female) · 5 locations
-
Caring Recharge Project for Caregivers of Individuals With Alzheimer's Disease
NCT07764185 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
NCT05231798 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NCT06189963 ·
Phase: Phase 1, Phase 2 ·
Ages: 40 Years to 85 Years ·
Sex: All (male and female) · 8 locations
-
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
NCT07066826 ·
Phase: Phase 2, Phase 3 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Clinical Trial on Agitation in Alzheimer's Dementia
NCT05543681 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 31 locations
-
Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
NCT07279740 ·
Phase: Phase 2 ·
Ages: No age limits stated ·
Sex: All (male and female) · 1 location
-
Communication Bridge 3 Study
NCT06191198 ·
Phase: Phase 2 ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female) · 1 location
-
DORA and LP in Alzheimer's Disease Biomarkers
NCT06274528 ·
Phase: Phase 2 ·
Ages: 65 Years and older ·
Sex: All (male and female) · 1 location
-
Daridorexant for Alzheimer Disease Prevention
NCT07213349 ·
Phase: Phase 2 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Daridorexant to Prevent Post-cardiotomy Delirium
NCT07217912 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 1 location
-
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
NCT06052254 ·
Phase: Phase 2 ·
Ages: No age limits stated ·
Sex: All (male and female) · 9 locations
-
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
NCT06041789 ·
Phase: Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 2 locations
-
Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
NCT04436081 ·
Phase: Phase 2 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease
NCT06850597 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Exercise to Improve Brain Health in Older African Americans
NCT05597124 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 1 location
-
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
NCT06362707 ·
Phase: Phase 2 ·
Ages: 50 Years to 100 Years ·
Sex: All (male and female) · 6 locations
-
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
NCT05374278 ·
Phase: Phase 1, Phase 2 ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
GnRH Therapy on Cognition in Down Syndrome
NCT04390646 ·
Phase: Phase 2, Phase 3 ·
Ages: 16 Years to 50 Years ·
Sex: All (male and female) · 1 location
-
Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
NCT07512362 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
NCT06781333 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
NCT07651319 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years to 86 Years ·
Sex: All (male and female) · 1 location
-
Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)
NCT06597942 ·
Phase: Phase 1, Phase 2 ·
Ages: 55 Years to 100 Years ·
Sex: All (male and female) · 1 location
-
Levetiracetam for Persons at Risk for Alzheimer's Disease
NCT07477431 ·
Phase: Phase 2 ·
Ages: 55 Years to 85 Years ·
Sex: All (male and female) · 2 locations
-
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
NCT04576793 ·
Phase: Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 1 location
-
Low-Dose Radiotherapy for Alzheimer's Disease
NCT07693140 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 1 location
-
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
NCT04684602 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease
NCT07741071 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 2 locations
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
NCT06582706 ·
Phase: Phase 1, Phase 2 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT06467539 ·
Phase: Phase 2 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Open-Label Extension Protocol to SNK01-AD01 Study
NCT07228078 ·
Phase: Phase 2 ·
Ages: 40 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 33 locations
-
Ozanimod in Patients With Alzheimer's Disease
NCT06862960 ·
Phase: Phase 2 ·
Ages: 55 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
NCT02649985 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
NCT04902703 ·
Phase: Phase 2 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Repurposing Siponimod for Alzheimer's Disease
NCT06639282 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Rifaximin SSD in Dementia Trial
NCT06718686 ·
Phase: Phase 1, Phase 2 ·
Ages: 65 Years and older ·
Sex: All (male and female) · 1 location
-
Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease
NCT07553338 ·
Phase: Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 1 location
-
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472 ·
Phase: Phase 2, Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 49 locations
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 9 locations
-
Senicapoc in Alzheimer's Disease
NCT04804241 ·
Phase: Phase 2 ·
Ages: 55 Years to 85 Years ·
Sex: All (male and female) · 2 locations
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
NCT05565833 ·
Phase: Phase 2 ·
Ages: 65 Years and older ·
Sex: All (male and female) · 1 location
-
Sleep Trial to Prevent Alzheimer's Disease
NCT04629547 ·
Phase: Phase 2 ·
Ages: 65 Years and older ·
Sex: All (male and female) · 1 location
-
Stem Cell Therapy for Early Alzheimer's Disease
NCT06775964 ·
Phase: Phase 1, Phase 2 ·
Ages: 60 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
NCT07221344 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 3 locations
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321 ·
Phase: Phase 2 ·
Ages: 55 Years to 80 Years ·
Sex: All (male and female) · 38 locations
-
Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers
NCT07399171 ·
Phase: Phase 2 ·
Ages: 50 Years to 75 Years ·
Sex: All (male and female) · 3 locations
-
Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
NCT07027072 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 8 locations
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 78 locations
-
Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone
NCT05282550 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female) · 1 location
-
The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease
NCT07457125 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 1 location
-
Transcranial Pulse Stimulation for Alzheimer's Disease
NCT07143734 ·
Phase: Phase 2 ·
Ages: 60 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)
NCT04601038 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female) · 1 location
-
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
NCT03503331 ·
Phase: Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 1 location
-
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
NCT07012993 ·
Phase: Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female) · 1 location
-
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
NCT06120049 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female) · 4 locations